Hemophagocytic lymphohistiocytosis after chemotherapy for multiple myeloma.
Secondary hemophagocytic lymphohistiocytosis has been reported after infections in immunocompromised hosts or in association with several malignancies. We report a case of secondary hemophagocytic syndrome after chemotherapy for multiple myeloma, which responded dramatically to dexamethasone, etoposide, and cyclosporin A.
Terrovitis
John V
JV
University of Athens School of Medicine, Department of Clinical Therapeutics, Alexandra Hospital, Greece. iterr@otenet.gr
Matsouka
Charis
C
Anagnostopoulos
Athanassios
A
Anastasiou-Nana
Maria I
MI
Dimopoulos
Athanassios Meletios
AM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001707:Biopsy, Needle; D001853:Bone Marrow / Q000473:pathology; D016572:Cyclosporine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D015616:Histiocytosis, Non-Langerhans-Cell / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D005047:Etoposide; D003907:Dexamethasone; D016572:Cyclosporine